Advertisement

Current Urology Reports

, 15:437 | Cite as

Confocal Laser Endomicroscopy of Bladder and Upper Tract Urothelial Carcinoma: A New Era of Optical Diagnosis?

  • Stephanie P. Chen
  • Joseph C. Liao
Urothelial Cancer (A Sagalowsky, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Urothelial Cancer

Abstract

Urothelial carcinoma of the bladder and upper tract pose significant diagnostic and therapeutic challenges. White light endoscopy plays a central role in the management of urothelial carcinoma but has several well-recognized shortcomings. New optical imaging technologies may improve diagnostic accuracy, enhance local cancer control, and better stratify treatment options. Confocal laser endomicroscopy enables dynamic imaging of the cellular structures below the mucosal surface and holds promise in providing real time optical diagnosis and grading of urothelial carcinoma. A variety of imaging probes are available that are compatible with the full spectrum of cystoscopes and ureteroscopes. We review the underlying principles and technique of confocal laser endomicroscopy in the urinary tract, with emphasis on specific application towards urothelial carcinoma. While the available data are largely related to urothelial carcinoma of the bladder, the lessons learned are directly applicable to the upper tract, where the clinical needs are significant. Ongoing efforts to optimize this technology offer an exciting glimpse into future advances in optical imaging and intraoperative image guidance.

Keywords

Urothelial carcinoma Bladder cancer Upper tract Optical imaging Microscopy 

Notes

Acknowledgments

The authors thank current and past members of the Liao Laboratory, particularly Katherine Wu and Kathy Mach, for technical support and helpful discussions. Funding support was provided in part by Stanford University School of Medicine MedScholars Fellowship (to S.P.C.) and NIH R01 CA160986 (to J.C.L.).

Compliance with Ethics Guidelines

Conflict of Interest

Stephanie P. Chen and Dr. Joseph C. Liao each declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2010 incidence and mortality web-based report. (U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2013).Google Scholar
  2. 2.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.PubMedCrossRefGoogle Scholar
  3. 3.
    Kirkali Z et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4–34.PubMedCrossRefGoogle Scholar
  4. 4.
    Morgan TM, Clark PE. Bladder cancer. Curr Opin Oncol. 2010;22:242–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Sylvester RJ et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–77.PubMedCrossRefGoogle Scholar
  6. 6.
    Cauberg Evelyne CC, de la Rosette JJMCH, de Reijke TM. Emerging optical techniques in advanced cystoscopy for bladder cancer diagnosis: A review of the current literature. Indian J Urol IJU J Urol Soc India. 2011;27:245–51.CrossRefGoogle Scholar
  7. 7.
    Rouprêt M et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol. 2011;59:584–94.PubMedCrossRefGoogle Scholar
  8. 8.
    Hall MC et al. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology. 1998;52:594–601.PubMedCrossRefGoogle Scholar
  9. 9.
    Linton KD, Catto JW. Upper tract urothelial carcinoma. J Clin Urol. 2013;6:272–9.Google Scholar
  10. 10.
    Azémar M-D, Comperat E, Richard F, Cussenot O, Rouprêt M. Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: frequency, risk factors, and surveillance. Urol Oncol. 2011;29:130–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Lee CSD, Yoon CY, Witjes JA. The past, present and future of cystoscopy: the fusion of cystoscopy and novel imaging technology. BJU Int. 2008;102:1228–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Liu J-J, Droller MJ, Liao JC. New optical imaging technologies for bladder cancer: considerations and perspectives. J Urol. 2012;188:361–8.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.•
    Wu K et al. Dynamic real-time microscopy of the urinary tract using confocal laser endomicroscopy. Urology. 2011;78:225–31. This paper describes the suggested optical diagnostic criteria for normal urothelium, benign inflammatory urothelium, low grade urothelial carcinoma, and high grade urothelial carcinoma.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Schmidbauer J et al. Improved detection of urothelial carcinoma in situ with hexaminolevulinate fluorescence cystoscopy. J Urol. 2004;171:135–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Fradet Y et al. A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007;178:68–73. discussion 73.PubMedCrossRefGoogle Scholar
  16. 16.
    Jocham D et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, phase III multicenter study. J Urol. 2005;174:862–6. discussion 866.PubMedCrossRefGoogle Scholar
  17. 17.
    Kolozsy Z. Histopathological ‘self control’ in transurethral resection of bladder tumours. Br J Urol. 1991;67:162–4.PubMedCrossRefGoogle Scholar
  18. 18.
    Babjuk M, Soukup V, Petrík R, Jirsa M, Dvorácek J. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer. BJU Int. 2005;96:798–802.PubMedCrossRefGoogle Scholar
  19. 19.
    Daniltchenko DI et al. Long-term benefit of 5-aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol. 2005;174:2129–33. discussion 2133.PubMedCrossRefGoogle Scholar
  20. 20.
    Klän R, Loy V, Huland H. Residual tumor discovered in routine second transurethral resection in patients with stage T1 transitional cell carcinoma of the bladder. J Urol. 1991;146:316–8.PubMedGoogle Scholar
  21. 21.
    Brausi M et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol. 2002;41:523–31.PubMedCrossRefGoogle Scholar
  22. 22.
    Margulis V et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer. 2009;115:1224–33.PubMedCrossRefGoogle Scholar
  23. 23.
    Straub J, Strittmatter F, Karl A, Stief CG, Tritschler S. Ureterorenoscopic biopsy and urinary cytology according to the 2004 WHO classification underestimate tumor grading in upper urinary tract urothelial carcinoma. Urol Oncol. 2013;31:1166–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Wang JK, Tollefson MK, Krambeck AE, Trost LW, Thompson RH. High rate of pathologic upgrading at nephroureterectomy for upper tract urothelial carcinoma. Urology. 2012;79:615–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Smith AK et al. Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology. 2011;78:82–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Tavora F et al. Small endoscopic biopsies of the ureter and renal pelvis: pathologic pitfalls. Am J Surg Pathol. 2009;33:1540–6.PubMedCrossRefGoogle Scholar
  27. 27.
    Cutress ML et al. Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int. 2012;110:614–28.PubMedCrossRefGoogle Scholar
  28. 28.
    Elliott DS, Segura JW, Lightner D, Patterson DE, Blute ML. Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney. Urology. 2001;58:174–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Gadzinski AJ, Roberts WW, Faerber GJ, Wolf Jr JS. Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol. 2010;183:2148–53.PubMedCrossRefGoogle Scholar
  30. 30.
    Lopez A, Liao JC. Emerging endoscopic imaging technologies for bladder cancer detection. Curr Urol Rep. 2014;15:406.PubMedCrossRefGoogle Scholar
  31. 31.•
    Sonn GA et al. Optical biopsy of human bladder neoplasia with in vivo confocal laser endomicroscopy. J Urol. 2009;182:1299–305. This paper was the initial feasibility study of in vivo confocal laser endomicroscopy in the urinary tract.PubMedCrossRefGoogle Scholar
  32. 32.
    Neumann H, Kiesslich R, Wallace MB, Neurath MF. Confocal laser endomicroscopy: technical advances and clinical applications. Gastroenterology. 2010;139:388–92. 392.e1–2.PubMedCrossRefGoogle Scholar
  33. 33.
    Thiberville L, Salaün M. Bronchoscopic advances: on the way to the cells. Respir Int Rev Thorac Dis. 2010;79:441–9.Google Scholar
  34. 34.
    Sonn GA et al. Fibered confocal microscopy of bladder tumors: an ex vivo study. J Endourol Endourol Soc. 2009;23:197–201.CrossRefGoogle Scholar
  35. 35.•
    Chang TC, Liu J-J, Liao JC. Probe-based confocal laser endomicroscopy of the urinary tract: the technique. J Vis Exp JoVE. 2013;e4409. doi: 10.3791/4409. This on-line video paper demonstrates a step-by-step approach of confocal laser endomicroscopy in the lower urinary tract.
  36. 36.
    Wallace MB et al. The safety of intravenous fluorescein for confocal laser endomicroscopy in the gastrointestinal tract. Aliment Pharmacol Ther. 2010;31:548–52.PubMedCrossRefGoogle Scholar
  37. 37.
    Becker V et al. High-resolution miniprobe-based confocal microscopy in combination with video mosaicing (with video). Gastrointest Endosc. 2007;66:1001–7.PubMedCrossRefGoogle Scholar
  38. 38.•
    Chang TC et al. Interobserver agreement of confocal laser endomicroscopy for bladder cancer. J Endourol Endourol Soc. 2013;27:598–603. This paper describes the interobserver agreement of confocal laser endomicroscopy of bladder lesions and provides an updated optical diagnostic criteria.CrossRefGoogle Scholar
  39. 39.
    Aron M et al. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia. Am J Surg Pathol. 2013;37:1815–23.PubMedCrossRefGoogle Scholar
  40. 40.
    Wallace MB et al. Preliminary accuracy and interobserver agreement for the detection of intraepithelial neoplasia in Barrett’s esophagus with probe-based confocal laser endomicroscopy. Gastrointest Endosc. 2010;72:19–24.PubMedCentralPubMedCrossRefGoogle Scholar
  41. 41.
    Viera AJ, Garrett JM. Understanding interobserver agreement: the kappa statistic. Fam Med. 2005;37:360–3.PubMedGoogle Scholar
  42. 42.
    Kuiper T, Kiesslich R, Ponsioen C, Fockens P, Dekker E. The learning curve, accuracy, and interobserver agreement of endoscope-based confocal laser endomicroscopy for the differentiation of colorectal lesions. Gastrointest Endosc. 2012;75:1211–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Gómez V et al. Interobserver agreement and accuracy among international experts with probe-based confocal laser endomicroscopy in predicting colorectal neoplasia. Endoscopy. 2010;42:286–91.PubMedCrossRefGoogle Scholar
  44. 44.
    Lee YC et al. Interobserver reliability in the endoscopic diagnosis and grading of Barrett’s esophagus: an Asian multinational study. Endoscopy. 2010;42:699–704.PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Kiesslich R et al. In vivo histology of Barrett’s esophagus and associated neoplasia by confocal laser endomicroscopy. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2006;4:979–87.Google Scholar
  46. 46.
    Gaddam S et al. Novel probe-based confocal laser endomicroscopy criteria and interobserver agreement for the detection of dysplasia in Barrett’s esophagus. Am J Gastroenterol. 2011;106:1961–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Bui D, Mach KE, Lopez A, Liu JJ, Chang T, Lavelle J, et al. Optical biopsy of upper tract urothelial carcinoma with confocal laser endomicroscopy. Eur Urol. 2014;13:e630.CrossRefGoogle Scholar
  48. 48.
    André B, Vercauteren T, Buchner AM, Wallace MB, Ayache N. A smart atlas for endomicroscopy using automated video retrieval. Med Image Anal. 2011;15:460–76.PubMedCrossRefGoogle Scholar
  49. 49.
    André B et al. Software for automated classification of probe-based confocal laser endomicroscopy videos of colorectal polyps. World J Gastroenterol WJG. 2012;18:5560–9.CrossRefGoogle Scholar
  50. 50.
    Hsiung P-L et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med. 2008;14:454–8.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Becker A et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol. 2001;19:327–31.PubMedCrossRefGoogle Scholar
  52. 52.
    Sturm MB et al. Targeted imaging of esophageal neoplasia with a fluorescently labeled peptide: first-in-human results. Sci Transl Med. 2013;5:184ra61.PubMedCrossRefGoogle Scholar
  53. 53.
    Miller SJ et al. In vivo fluorescence-based endoscopic detection of colon dysplasia in the mouse using a novel peptide probe. PLoS One. 2011;6:e17384.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Thekkek N et al. Pre-clinical evaluation of fluorescent deoxyglucose as a topical contrast agent for the detection of Barrett’s-associated neoplasia during confocal imaging. Technol Cancer Res Treat. 2011;10:431–41.PubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of UrologyStanford University School of MedicineStanfordUSA
  2. 2.Veterans Affairs Palo Alto Health Care SystemPalo AltoUSA

Personalised recommendations